Ligand presents the first phase I human data lead SARM LGD-4033 Molecule At the International Congress of Endocrinology

– The systemic exposure of the CPS-4033 increases in proportion to dose after a single oral dose. Sustained systemic exposure was observed in plasma levels of significant detectable PCD-4033 one week after the dose. PCD-4033 of the half-life is consistent with the treatment with daily oral administration.– PCD-4033 was well tolerated in healthy men after a single oral dose of 22 mg, the highest dose tested. There are no serious adverse events or clinically significant dose-related adverse events were reported.

Dr. Mondal said: ‘The Complementary and Alternative Medicine has become very important as an adjuvant in cancer patients, and to alleviate the side effects of chemotherapy and to improve their anti-tumor effects. We have shown that at low concentrations can be a great advantage for the development of new anticancer drugs, particularly against hormone-refractory prostate cancers, which are much more difficult to treat. ‘

Ligand Pharmaceuticals Incorporated announced that data from a Phase I study with the selective androgen receptor modulator LGD-4033 was presented today during a poster presentation at the 14 th International Congress on Endocrinology Kyoto, Japan.

This phase I clinical study was the first study in humans of LGD-4033 and evaluated the safety, tolerability and pharmacokinetic profile of the molecule in a single dose escalation, double-blind, placebo-controlled study in 48 healthy volunteers.